Q-omics provides the consensus-scored KDM1B profile across patient tissues and cancer cell-line models. KDM1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, KDM1B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, KDM1B protein abundance shows 20,171 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, HNSC, and LSCC as cancer lineages where KDM1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM1B survival associations across molecular data types. KDM1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM1B RNA expression–survival associations across cancer types. High KDM1B expression shows unfavorable associations in KICH, ACC, LIHC and SARC, but favorable associations in KIRC and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for KDM1B RNA expression.
This table summarizes KDM1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM1B shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, BLCA, LUAD and LIHC. The HNSC box plot shows higher KDM1B RNA expression in tumor versus normal tissue (log2 FC = +1.151, t-test p < 0.001).
This table shows molecular features associated with KDM1B in patient tissues and cancer cell lines. In patient samples, KDM1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
